StockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Sell

ANI Pharmaceuticals (NASDAQ:ANIPGet Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

A number of other analysts have also recently commented on the stock. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price on the stock. Truist Financial boosted their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Finally, Piper Sandler started coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $77.71.

Read Our Latest Stock Report on ANIP

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $59.35 on Tuesday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm’s fifty day simple moving average is $56.50 and its 200 day simple moving average is $58.63. The stock has a market cap of $1.25 billion, a P/E ratio of -107.91 and a beta of 0.73. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIPGet Free Report) last released its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same period in the prior year, the firm earned $1.05 earnings per share. ANI Pharmaceuticals’s revenue was up 12.5% on a year-over-year basis. As a group, research analysts predict that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. This represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,381 shares of company stock worth $2,441,556 over the last quarter. Company insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP lifted its position in shares of ANI Pharmaceuticals by 3.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock valued at $40,132,000 after buying an additional 21,053 shares in the last quarter. Sei Investments Co. raised its stake in ANI Pharmaceuticals by 27.8% during the 2nd quarter. Sei Investments Co. now owns 14,473 shares of the specialty pharmaceutical company’s stock worth $922,000 after acquiring an additional 3,152 shares during the period. Marshall Wace LLP purchased a new position in ANI Pharmaceuticals during the second quarter valued at approximately $253,000. AQR Capital Management LLC boosted its position in shares of ANI Pharmaceuticals by 44.8% in the second quarter. AQR Capital Management LLC now owns 17,527 shares of the specialty pharmaceutical company’s stock worth $1,116,000 after purchasing an additional 5,419 shares during the period. Finally, Millennium Management LLC raised its position in shares of ANI Pharmaceuticals by 1,005.8% during the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after purchasing an additional 209,272 shares during the period. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Featured Stories

Analyst Recommendations for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.